Switchable antibody-like proteins to control Alzheimer's-related proteins
Engineering Smart Antibody-like Protein Scaffolds with precision switches
Researchers are creating antibody-like proteins that can be turned on or off by light or drugs to control harmful proteins linked to Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11159813 on NIH RePORTER |
What this research studies
This project will engineer small antibody-like protein scaffolds that include built-in switches activated by light or chemicals. Scientists will test these switchable proteins in cells and Alzheimer's disease models to see if they can bind, move, or neutralize targets such as amyloid-beta-42. The approach aims to give fast, reversible control over disease-related proteins without altering a person's genes. Right now the work is laboratory and preclinical, so it is not yet a treatment people can receive.
Who could benefit from this research
Good fit: People with Alzheimer's disease or mild cognitive impairment related to amyloid pathology could be future candidates for clinical trials based on this work.
Not a fit: Patients with conditions unrelated to protein aggregation or those with very advanced neurodegeneration are less likely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could lead to new ways to turn off or redirect harmful proteins like amyloid-beta, potentially slowing or preventing Alzheimer's progression.
How similar studies have performed: Related optogenetic and chemogenetic tools have worked in cells and animal models, but applying switchable antibody-like scaffolds is a newer and less-tested strategy.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Zhou, Yubin — Texas A&m University Health Science Ctr
- Study coordinator: Zhou, Yubin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.